RRM3 Antibody

What is RRM3 and why is it important in molecular biology research?

RRM3 (RNA Recognition Motif 3) is one of three RNA recognition motifs found in the HuR/ELAVL1 protein, which plays crucial roles in differentiation and stress response primarily by stabilizing messenger RNA targets. Understanding RRM3 is particularly important because it mediates canonical RNA interactions and is involved in the dimerization of HuR, which is essential for its biological function . Research shows that RRM3 contributes significantly to full-length HuR activity both in vitro and in regulating target mRNA levels in human cells . While RRM1 and RRM2 have been well-characterized, the structure and function of RRM3 remained less clear until recent structural studies elucidated its role. RRM3-specific antibodies are valuable tools for investigating the unique contributions of this domain to RNA-binding protein dynamics.

How is RRM3 structurally and functionally distinct from other RNA recognition motifs?

RRM3 exhibits distinct structural and functional characteristics compared to other RNA recognition motifs:

What types of RRM3 antibodies are available for research applications?

Based on current research practices with similar RNA-binding protein domains, RRM3 antibodies typically available include:

• Monoclonal antibodies: Highly specific to single epitopes of RRM3, similar to the mouse monoclonal antibodies developed for related RNA-binding proteins . These provide consistent results across experiments with minimal batch-to-batch variation.

• Polyclonal antibodies: Recognize multiple epitopes on RRM3, offering higher sensitivity but potentially more cross-reactivity.

• Domain-specific antibodies: Designed to specifically target the RRM3 domain without cross-reactivity to RRM1 or RRM2.

• Phospho-specific antibodies: Target phosphorylated forms of RRM3, particularly at sites like Ser318, which has been implicated in regulating the interaction of full-length HuR with target mRNAs .

When selecting an RRM3 antibody, researchers should consider the specific application (western blotting, immunoprecipitation, immunofluorescence), species reactivity, and whether domain specificity is required for their research questions.

How can I optimize RRM3 antibody use in immunoprecipitation experiments?

Optimizing RRM3 antibody use in immunoprecipitation (IP) experiments requires careful consideration of several factors:

• Antibody selection: Choose antibodies that have been validated for IP applications. Monoclonal antibodies typically offer higher specificity but may recognize only a single epitope that could be masked during protein interactions.

• Crosslinking considerations: Since RRM3 is involved in both RNA binding and protein dimerization, consider whether formaldehyde or other crosslinking agents might be needed to preserve transient interactions. Use 0.1-1% formaldehyde for 10 minutes at room temperature for optimal crosslinking without overfixation.

• Buffer optimization:

  • For studying RNA-protein interactions: Include RNase inhibitors (40 U/mL) in your lysis buffer

  • For protein-protein interactions: Use buffers containing 150 mM NaCl, 0.5% NP-40, 50 mM Tris-HCl (pH 7.4)

  • For studying dimerization: Consider using buffers that preserve the native structure of the α-helical face of RRM3

• Control experiments: Include appropriate controls such as IgG controls and RRM3-depleted samples to verify antibody specificity.

• RNA-induced conformational changes: Since RRM3 undergoes conformational changes upon RNA binding that can affect antibody accessibility, consider performing IPs both in the presence and absence of RNase treatment to compare results .

For RNA immunoprecipitation (RIP) experiments specifically, pretreatment of cell lysates with DNase I (100 U/mL) for 15 minutes at 37°C can reduce background and improve specificity of RNA target identification.

What are the key considerations for using RRM3 antibodies in immunofluorescence studies?

When using RRM3 antibodies for immunofluorescence studies, researchers should consider:

For visualization of dynamic HuR-RNA interactions, consider super-resolution techniques such as STORM or PALM, which can provide spatial resolution down to 20nm, allowing better visualization of RRM3-containing ribonucleoprotein complexes.

How does phosphorylation of RRM3 affect antibody recognition and experimental outcomes?

Phosphorylation of RRM3, particularly at Ser318, significantly impacts its biological function and can affect antibody recognition in experimental settings . Key considerations include:

• Epitope masking: Phosphorylation can alter the three-dimensional structure of RRM3, potentially masking epitopes recognized by certain antibodies. This is especially relevant for antibodies targeting regions near known phosphorylation sites.

• Phospho-specific antibodies: For studying the functional consequences of RRM3 phosphorylation:

  • Use phospho-specific antibodies that selectively recognize Ser318 phosphorylation

  • Include appropriate controls with phosphatase treatment to confirm specificity

• Differential detection based on cellular conditions:

  • Stress conditions often alter RRM3 phosphorylation status

  • Cell cycle phase may influence phosphorylation patterns

• Impact on experimental outcomes:

• Experimental strategies:

  • When studying phosphorylation-dependent functions, consider using phosphomimetic (S318D) or phospho-null (S318A) mutations in combination with antibody-based detection

  • For temporal studies, combine phospho-specific antibodies with time-course experiments following stimulation

Understanding the phosphorylation state of RRM3 is crucial as it has been demonstrated to regulate the interaction of full-length HuR with target mRNAs, directly affecting experimental outcomes when studying RNA binding properties .

How can I use RRM3 antibodies to investigate dimerization mechanisms of HuR?

RRM3 plays a critical role in mediating HuR dimerization through its α-helical face, making antibodies against this domain valuable tools for studying this process . Strategic approaches include:

• Epitope-specific antibody selection:

  • Choose antibodies that target regions away from the dimerization interface to avoid interference with dimer formation

  • Alternatively, select antibodies specifically designed to recognize the dimerization interface for inhibition studies

• Proximity ligation assays (PLA):

  • Use two different antibodies (one targeting RRM3 and another targeting a different region of HuR) to visualize dimerization events in situ

  • PLA signals will only be generated when molecules are within 40nm of each other, providing evidence of dimerization

• Co-immunoprecipitation studies:

  • Use tagged versions of HuR (e.g., FLAG-HuR and HA-HuR) to demonstrate dimerization

  • Apply RRM3 antibodies to determine if they interfere with co-immunoprecipitation, indicating binding at dimerization interfaces

• FRET/BRET analysis:

  • Combine RRM3 antibody treatments with fluorescence/bioluminescence resonance energy transfer to measure dimerization dynamics

  • Changes in FRET/BRET efficiency after antibody treatment can reveal roles of specific epitopes in dimerization

• Size exclusion chromatography with antibody treatment:

  • Preincubate HuR with RRM3 antibodies before size exclusion chromatography

  • Shifts in elution profiles can indicate interference with dimerization

When designing experiments, remember that NMR experiments have identified conserved Trp261 as being particularly important in RRM3 dimerization . Targeting this region with specific antibodies or monitoring changes in this residue's environment can provide valuable insights into the dimerization mechanism.

What approaches can resolve contradictory results when using different RRM3 antibodies?

Contradictory results when using different RRM3 antibodies are not uncommon and can arise from several factors. Here's a systematic approach to resolve such discrepancies:

• Epitope mapping and antibody characterization:

  • Determine the precise epitopes recognized by each antibody through peptide arrays or hydrogen/deuterium exchange mass spectrometry

  • Create an epitope map of RRM3 to understand which structural or functional elements each antibody targets

• Conformational considerations:

  • RRM3 adopts different conformations when free, RNA-bound, or dimerized

  • Antibodies may preferentially recognize specific conformational states, explaining discrepant results

• Validation with multiple techniques:

  • Employ orthogonal methods (e.g., mass spectrometry, CRISPR knockout controls) to validate findings

  • Use at least two independent antibodies targeting different epitopes to confirm results

• Controlled expression systems:

  • Utilize systems with inducible HuR expression or domain deletions to validate antibody specificity

  • Test antibodies against RRM3 knockout/mutant samples as negative controls

• Systematic comparison protocol:

Remember that in vitro studies have reported both enhancement or negligible effects of ΔRRM3 on RNA binding in the context of full-length HuR , highlighting the complexity of RRM3 function and potentially explaining contradictory antibody-based results.

How can RRM3 antibodies be used to differentiate between various structural states of HuR?

RRM3 antibodies can be strategically employed to distinguish between the different structural states of HuR, providing valuable insights into its functional dynamics. According to structural studies, the three RRMs in full-length HuR are flexibly connected in the absence of RNA but adopt a more compact arrangement when RNA-bound . Here's how to leverage antibodies to detect these states:

• Conformation-specific antibody development:

  • Generate antibodies against epitopes that are only accessible in specific conformational states

  • Validate using known conditions that induce different structural states (e.g., presence/absence of target RNA)

• Accessibility-based approaches:

  • Perform limited proteolysis in different HuR states followed by antibody detection

  • Changes in proteolytic patterns combined with antibody recognition can reveal structural rearrangements

• FRET-based structural sensors:

  • Design systems with fluorophore-conjugated antibodies or Fab fragments targeting different RRM domains

  • Measure FRET efficiency changes upon RNA binding or dimerization

• Antibody competition assays:

  • Use combinations of different RRM-specific antibodies to determine epitope accessibility

  • Sequential or simultaneous binding can reveal which epitopes are mutually accessible

• Structural state differentiation protocol:

• In situ proximity labeling:

  • Combine antibody recognition with proximity labeling techniques (BioID, APEX)

  • Different structural states will yield distinct labeling patterns

Remember that as RRM3 is involved in both RNA binding and dimerization, careful experimental design is needed to distinguish these functions. NMR and SAXS analyses have shown that RNA binding induces significant conformational changes in full-length HuR , making antibodies valuable tools for capturing these dynamic structural transitions.

How can RRM3 antibodies be used in combination with advanced imaging techniques to study RNA granule dynamics?

RRM3 antibodies can be powerfully integrated with cutting-edge imaging techniques to investigate RNA granule dynamics, where HuR plays important regulatory roles:

• Super-resolution microscopy approaches:

  • STORM/PALM: Conjugate RRM3 antibodies with photoactivatable fluorophores to achieve 20nm resolution, revealing the nanoscale organization of HuR within RNA granules

  • SIM/STED: Use standard fluorophore-conjugated antibodies to achieve 100nm resolution with less specialized equipment

• Live-cell imaging strategies:

  • Implement Fab fragments of RRM3 antibodies conjugated to cell-permeable fluorophores

  • Use microinjection of labeled antibodies for intact cell observations of dynamic RRM3 localization

• Phase separation studies:

  • Since many RNA-binding proteins participate in liquid-liquid phase separation to form membraneless organelles, RRM3 antibodies can help investigate HuR's role in this process

  • Quantify partition coefficients of HuR in different cellular compartments using antibody-based detection

• Multiplexed imaging protocols:

• Stress response visualization:

  • Track RRM3/HuR redistribution during stress granule formation using pulse-chase antibody labeling

  • Combine with photoactivatable RNA analogues to simultaneously track RNA and RRM3

• Quantitative analysis approaches:

  • Implement single-particle tracking of antibody-labeled RRM3 to determine diffusion coefficients

  • Use pair-correlation analysis to quantify clustering dynamics

These approaches can help address how the dimerization properties of RRM3 contribute to RNA granule assembly and dynamics, building on studies showing that RRM3 dimerization is required for functional activity of full-length HuR .

What are the best practices for validating RRM3 antibody specificity for chromatin immunoprecipitation (ChIP) applications?

Validating RRM3 antibody specificity for chromatin immunoprecipitation requires rigorous controls to ensure reliable results, particularly because HuR functions primarily as an RNA-binding protein rather than a direct DNA-binding factor:

• Knockout/knockdown validation:

  • Perform ChIP in cells where HuR has been depleted via CRISPR/Cas9 or siRNA

  • The signal should be substantially reduced or eliminated in these samples

• Peptide competition assays:

  • Pre-incubate the antibody with excess immunizing peptide before ChIP

  • If the antibody is specific, the peptide should compete for binding and reduce ChIP signal

• Cross-reactivity assessment:

  • Test the antibody against recombinant RRM1, RRM2, and RRM3 domains

  • Quantify relative affinities to ensure domain specificity

• Sequential ChIP (re-ChIP):

  • Perform initial ChIP with an antibody against full-length HuR

  • Follow with a second ChIP using the RRM3-specific antibody

  • Enrichment indicates the same complexes contain both epitopes

• Validation protocol with multiple controls:

• Motif enrichment analysis:

  • Since HuR binds RNA with sequence preferences, analyze ChIP-seq data for enrichment of known HuR binding motifs

  • Absence of expected motifs may indicate non-specific antibody binding

When performing ChIP with RRM3 antibodies, remember that HuR may be recruited to chromatin indirectly through RNA or protein-protein interactions rather than direct DNA binding. Therefore, RNase treatment controls should be included to distinguish RNA-mediated from direct chromatin associations.

How can I optimize RRM3 antibodies for detecting posttranslational modifications that affect HuR function?

Detecting posttranslational modifications (PTMs) of RRM3 is crucial for understanding HuR regulation, particularly since phosphorylation of Ser318 has been implicated in modulating interactions with target mRNAs . Here's how to optimize antibody-based detection of these modifications:

• Modification-specific antibody development:

  • Generate antibodies against synthetic peptides containing the specific PTM of interest

  • Validate using both in vitro modified proteins and cellular extracts treated with appropriate modifying or demodifying enzymes

• Combined approaches for comprehensive PTM mapping:

  • Use general RRM3 antibodies for immunoprecipitation followed by mass spectrometry

  • Apply PTM-specific antibodies to verify individual modifications

• Multiplexed PTM detection:

  • Implement multi-color immunofluorescence using antibodies against different PTMs

  • Use proximity ligation assays to detect co-occurrence of multiple modifications

• Induction and inhibition validation:

  • Treat cells with stimuli known to induce specific PTMs (e.g., stress conditions for phosphorylation)

  • Use specific kinase/enzyme inhibitors to block modifications and confirm antibody specificity

• Optimization protocol for key RRM3 modifications:

• Extraction conditions optimization:

  • Modify lysis buffers to preserve PTMs (e.g., include phosphatase inhibitors for phosphorylation)

  • Consider rapid heat denaturation to inactivate modifying enzymes immediately upon lysis

• Contextual analysis:

  • Develop workflows to correlate PTM status with RRM3 localization and function

  • Use sequential immunoprecipitation to isolate subpopulations with specific modification patterns

Remember that structural studies indicate that the three RRM domains adopt different conformations depending on RNA binding status , which may affect the accessibility of PTMs to antibodies. Consider performing detection under both native and denaturing conditions to ensure comprehensive PTM profiling.

How can I optimize RRM3 antibodies for RNA immunoprecipitation sequencing (RIP-seq) experiments?

Optimizing RRM3 antibodies for RIP-seq requires careful consideration of several factors to ensure high specificity and comprehensive capture of RNA targets:

• Antibody selection criteria:

  • Choose antibodies validated for immunoprecipitation applications

  • Prefer antibodies targeting regions of RRM3 that are not directly involved in RNA binding

  • Consider epitope accessibility in the context of RRM3's role in both RNA binding and dimerization

• Crosslinking optimization:

  • Test both formaldehyde crosslinking (1% for 10 minutes) and UV crosslinking (254nm, 400mJ/cm²)

  • Compare results with no-crosslinking approaches to evaluate artificial interactions

• RNase treatment controls:

  • Include RNase-treated controls to distinguish direct protein binding from RNA-mediated interactions

  • Use gradient RNase treatments to determine the footprint size of protected RNA fragments

• Buffer optimization protocol:

• Sequential RIP strategy:

  • First IP with antibodies against full-length HuR

  • Re-IP with RRM3-specific antibodies

  • This approach enriches for RNA targets specifically associated with RRM3

• Library preparation considerations:

  • Implement unique molecular identifiers (UMIs) to control for PCR duplication

  • Consider size selection to focus on either small RNAs or larger transcripts

• Computational validation:

  • Compare RIP-seq results with known HuR binding motifs (U/AU-rich elements)

  • Implement peak calling algorithms specific for RIP-seq data

This optimization is particularly important given that RRM3 has been shown to bind to U- and AU-rich RNAs as well as long poly-A stretches , and its binding properties may differ from those of RRM1,2.

What strategies can improve the specificity of RRM3 antibodies when studying HuR in complex with other RNA-binding proteins?

Improving antibody specificity when studying RRM3/HuR in ribonucleoprotein complexes requires specialized approaches to distinguish direct interactions from indirect associations:

• Epitope accessibility evaluation:

  • Map regions of RRM3 that become inaccessible in different protein complexes

  • Select antibodies targeting epitopes that remain exposed in the complexes of interest

• Proximity-dependent labeling:

  • Combine antibody-based detection with BioID or APEX2 proximity labeling

  • This identifies proteins in close proximity to RRM3 regardless of complex stability

• Competitive binding assessments:

  • Use peptides derived from known RRM3-interacting proteins to compete for binding

  • Monitor how these competitions affect antibody recognition

• Multi-step purification strategy:

• Cross-validation with antibodies against known partners:

  • Perform co-immunoprecipitation with antibodies against established HuR-interacting proteins

  • Confirm presence of HuR/RRM3 in these complexes using RRM3-specific antibodies

• Solution-based approaches:

  • Implement fluorescence correlation spectroscopy with fluorophore-conjugated antibodies

  • Measure diffusion coefficients to distinguish free HuR from complex-associated forms

• Structural epitope mapping:

  • Use hydrogen/deuterium exchange mass spectrometry to identify regions protected in complexes

  • Design antibodies against regions that remain exposed

These approaches are particularly relevant given that RRM3 is implicated in protein-protein interactions and HuR multimerization on mRNA targets , making it challenging to distinguish these different functional states using standard antibody approaches.

How can RRM3 antibodies be used to investigate the dynamic conformational changes in HuR during RNA binding?

RRM3 antibodies can be powerful tools for investigating the conformational dynamics of HuR, particularly since structural studies have shown that the three RRM domains in HuR are flexibly connected when free but adopt a more compact arrangement when RNA-bound :

• Conformation-sensitive antibody screening:

  • Test panels of antibodies for differential recognition of free versus RNA-bound HuR

  • Identify antibodies that selectively recognize specific conformational states

• Real-time binding studies:

  • Use surface plasmon resonance (SPR) with immobilized antibodies

  • Measure binding kinetics of HuR in the presence and absence of target RNAs

• FRET-based conformational sensors:

  • Design systems with donor-labeled antibodies against one RRM domain and acceptor-labeled antibodies against another

  • Measure FRET efficiency changes upon RNA addition to detect domain rearrangements

• Limited proteolysis coupled with antibody detection:

  • Perform time-course proteolysis on free and RNA-bound HuR

  • Use domain-specific antibodies to track which regions become protected or exposed

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS) with antibody validation:

• Single-molecule studies:

  • Implement antibody-based fluorescence techniques at the single-molecule level

  • Observe conformational transitions in real-time using techniques like smFRET

• In-cell conformational analysis:

  • Use split-fluorescent protein complementation with one fragment fused to an antibody fragment

  • The other fragment attached to another domain-specific binder

  • Signal generation indicates proximity of domains in specific conformational states